2020
Preventing COVID-19 Collateral Damage
Shepherd J, Friedland G. Preventing COVID-19 Collateral Damage. Clinical Infectious Diseases 2020, 71: 1564-1567. PMID: 32544952, PMCID: PMC7337641, DOI: 10.1093/cid/ciaa772.Peer-Reviewed Original ResearchConfronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response
Edelman EJ, Aoun-Barakat L, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.Peer-Reviewed Original Research
2017
A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis
Kaplan SR, Topal J, Sosa L, Malinis M, Huttner A, Malhotra A, Friedland G. A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis. Journal Of Clinical Tuberculosis And Other Mycobacterial Diseases 2017, 10: 9-16. PMID: 31720380, PMCID: PMC6830180, DOI: 10.1016/j.jctube.2017.12.004.Peer-Reviewed Case Reports and Technical NotesDrug-resistant tuberculosisResistant tuberculosisMulti-drug resistant (MDR) TBCentral nervous system tuberculomasCentral nervous system tuberculosisNervous system tuberculosisGlobal public health concernCause of deathIncrease of patientsDrug-resistant strainsPublic health concernExtrapulmonary diseaseMiddle-income countriesNeurological symptomsTreatment challengesTuberculosisHealth concernYoung menPatientsTuberculomaSymptomsDiseaseTurning the tide against tuberculosis
Padayatchi N, Naidu N, Friedland G, Naidoo K, Conradie F, Naidoo K, O’Donnell M. Turning the tide against tuberculosis. International Journal Of Infectious Diseases 2017, 56: 6-9. PMID: 28167256, DOI: 10.1016/j.ijid.2017.01.012.Peer-Reviewed Original Research
2015
Lymphadenopathy/lymphadenitis
Shenoi S, Friedland G. Lymphadenopathy/lymphadenitis. 2015, 184-191. DOI: 10.1017/cbo9781139855952.033.Peer-Reviewed Original Research
2008
Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa
Mosam A, Hurkchand H, Cassol E, Page T, Cassol S, Bodasing U, Aboobaker J, Dawood H, Friedland G, Coovadia H. Characteristics of HIV-1-associated Kaposi's sarcoma among women and men in South Africa. International Journal Of STD & AIDS 2008, 19: 400-405. PMID: 18595878, DOI: 10.1258/ijsa.2008.007301.Peer-Reviewed Original ResearchConceptsHIV-1-associated Kaposi's sarcomaKaposi's sarcomaCD4/CD8 cell countsHIV-1 viral loadCD8 cell countsCutaneous Kaposi's sarcomaPoor disease prognosisVirological featuresViral loadClinical parametersPatients 99Male ratioSevere diseaseDisease prognosisCell countSarcomaHIVDescriptive studyAfrican settingEqual femalePatientsOne-thirdDiseaseFemalesWomen
2007
Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies
Friedland G, Harries A, Coetzee D. Implementation Issues in Tuberculosis/HIV Program Collaboration and Integration: 3 Case Studies. The Journal Of Infectious Diseases 2007, 196: s114-s123. PMID: 17624820, DOI: 10.1086/518664.Peer-Reviewed Original ResearchConceptsTB/HIV service integrationHIV service integrationNeeds of patientsPublic health approachWorld Health OrganizationHIV diseaseNational TuberculosisHIV programsHIV interactionsInfection influenceHealth approachSuccessful outcomeTuberculosisDiseaseHealth OrganizationLarge national programProgram settingsSmall demonstration projectsMost settingsOutcomesImplementation of programsProgram collaborationNational programLarge populationService integration
2006
HIV Medication Adherence
Friedland GH. HIV Medication Adherence. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s3-s9. PMID: 17133202, DOI: 10.1097/01.qai.0000248333.44449.ea.Peer-Reviewed Original Research
2004
Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries
Friedland G, Karim S, Karim Q, Lalloo U, Jack C, Gandhi N, Sadr W. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases 2004, 38: s421-s428. PMID: 15156433, DOI: 10.1086/421407.Peer-Reviewed Original ResearchConceptsHIV infectionAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionTherapy programHIV/AIDS careObserved therapy programActive antiretroviral therapyImmunodeficiency virus infectionImmune deficiency syndromeBurden of diseaseResource-limited countriesResource limited countriesHIV/AIDSHIV diseaseTuberculosis careDisease burdenDeficiency syndromeAIDS careVirus infectionTuberculosisInfectionMajor causeDiseaseTherapyInadequate access
2003
Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy
Schreibman T, Friedland G. Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy. Clinical Infectious Diseases 2003, 38: 257-262. PMID: 14699459, DOI: 10.1086/380792.Peer-Reviewed Original ResearchConceptsTotal lymphocyte countCD4 cell countAntiretroviral therapyCell countLymphocyte countHuman immunodeficiency virus (HIV) diseaseOpportunistic infection prophylaxisPotential surrogate markerResource-limited settingsHIV diseaseInfection prophylaxisLaboratory markersOpportunistic infectionsSurrogate markerDisease progressionClinical utilityImmune functionTherapeutic interventionsTherapyKey laboratory measurementsMonitoring responseVirus diseaseLack of availabilityDiseaseCount
1996
Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.
Wetherill PE, Landry ML, Alcabes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1996, 12: 33-7. PMID: 8624758, DOI: 10.1097/00042560-199605010-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibodies, MonoclonalAntigens, ViralCross-Sectional StudiesCytomegalovirusCytomegalovirus InfectionsCytomegalovirus RetinitisFemaleFluorescent Antibody TechniqueHIV SeropositivityHIV-1HumansLeukocytesMaleMiddle AgedPredictive Value of TestsRetrospective StudiesViral Matrix ProteinsViremiaConceptsCMV antigenemia testCMV diseaseAntigenemia testCMV antigenemiaHIV diseaseCytomegalovirus antigenemia testPositive CMV antigenemiaLife-threatening infectionsDiagnostic techniquesAntigenemia levelsAntigenemia resultsCMV retinitisCytomegalovirus infectionCMV cultureClinical evidenceOphthalmologic examPatientsDiseaseRapid diagnosisAntigenemiaInfectionDiagnosisQuantitative diagnostic techniqueRetinitisHIVStavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials
1988
Transmission of the human immunodeficiency virus: an updated review.
Friedland G, Klein R. Transmission of the human immunodeficiency virus: an updated review. International Nursing Review 1988, 35: 44-52, 54. PMID: 3283068.Peer-Reviewed Original Research
1987
Inability to predict diagnosis in febrile intravenous drug abusers.
Marantz P, Linzer M, Feiner C, Feinstein S, Kozin A, Friedland G. Inability to predict diagnosis in febrile intravenous drug abusers. Annals Of Internal Medicine 1987, 106: 823-8. PMID: 3579068, DOI: 10.7326/0003-4819-106-6-823.Peer-Reviewed Original ResearchConceptsIntravenous drug abusersFinal diagnosisEmergency roomTrivial illnessDrug abusersDistribution of diseaseInfective endocarditisConsecutive admissionsPhysicians' predictionsClinical dataDiagnostic predictionClinical informationPredictive valuePatientsDiagnosisIllnessLaboratory dataEndocarditisAbusersHospitalizationPneumoniaAdmissionFeverDiseaseThe Acquired Immunodeficiency Syndrome: General Overview
Friedland G. The Acquired Immunodeficiency Syndrome: General Overview. International Journal Of Neuroscience 1987, 32: 677-686. PMID: 3647936, DOI: 10.3109/00207458709043322.Peer-Reviewed Original Research
1984
Nosocomial Endocarditis
Friedland G, von Reyn C, Levy B, Arbeit R, Dasse P, Crumpacker C. Nosocomial Endocarditis. Infection Control And Hospital Epidemiology 1984, 5: 284-288. PMID: 6564081, DOI: 10.1017/s0195941700060343.Peer-Reviewed Original ResearchConceptsCommunity-acquired endocarditisNosocomial endocarditisIntracardiac prosthetic materialNosocomial infective endocarditisPercent of patientsValvular heart diseaseBeth Israel HospitalSite of originClinical presentationInfective endocarditisUrinary sourceHeart diseaseProsthetic valvesEndocarditisInvasive proceduresGreater incidenceHigh mortalityPatientsProsthetic materialIsrael HospitalBacteremiaSeven-year periodDiseaseTherapeutic practiceHospital
1981
Infective endocarditis: an analysis based on strict case definitions.
Von Reyn C, Levy B, Arbeit R, Friedland G, Crumpacker C. Infective endocarditis: an analysis based on strict case definitions. Annals Of Internal Medicine 1981, 94: 505-18. PMID: 7011141, DOI: 10.7326/0003-4819-94-4-505.Peer-Reviewed Original ResearchConceptsStrict case definitionValvular diseaseCase definitionAdvanced mean ageShorter mean durationNosocomial endocarditisProsthesis endocarditisNeurologic eventsPossible endocarditisCardiac surgeryHeart failureInfective endocarditisMean ageMean durationEarly recognitionClinical studiesEndocarditisHigh incidenceInvasive proceduresViridans streptococciLarge seriesSuspect casesStaphylococcus aureusMortalityDisease